Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Daniel, Peter Prof. Dr. (1) Hinz, Michael Dr. (2) Lusatis, Simone (1) Mathas, Stephan Dr. (9) Scheidereit, Claus Prof. Dr. (3) Selbach, Matthias Prof. Dr. (5) Wollert-Wulf, Brigitte (2) (-) Janz, Martin Dr. (5) (-) Biologie maligner Lymphome (5) Genetik und Genomik von Herz- Kreislauferkrankungen (1) 1999 (1) 2000 (1) (-) 2002 (1) 2003 (3) 2004 (2) 2005 (2) (-) 2006 (4) 2007 (2) 2008 (2) 2009 (3) 2010 (1) 2011 (4) 2012 (2) 2013 (2) 2014 (2) 2015 (2) 2016 (1) 2017 (3) 2018 (1) 2020 (4) 2021 (3) 2022 (4) 2023 (6) 2024 (1) 5 Ergebnisse: Active Filter: Janz, Martin Dr.Biologie maligner Lymphome20022006 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken